The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of aneurysm and stenosis are listed in the xience v everolimus eluting coronary stent systems instructions for use (ifu) as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the patient presented on (b)(6) 2021 for the procedure to treat a moderately calcified, mildly tortuous, 99% stenosed de novo lesion in the right coronary artery (rca).A 4x23mm xience v drug eluting stent (des) was implanted without issue and no residual stenosis.The patient was rehospitalized on (b)(6) 2022 with unstable angina.Imaging revealed an aneurysm at the proximal origin of the stent with 100% in-stent restenosis (isr).Patient was kept on medical management.No additional information was provided.
|